Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed an increase in revenue but also a widening net loss due to higher R&D expenses. The cash reserves are decreasing, raising concerns about financial sustainability. The Q&A section did not provide clarity on management's responses, which may contribute to uncertainty. Despite a positive revenue growth, the financial health and lack of strategic updates suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8%.
Key Financial Performance
Revenue Intellia Therapeutics reported revenue of $12.3 million for Q4 2025, which represents a 15% increase year-over-year. The increase was primarily driven by higher collaboration revenue from existing partnerships.
Net Loss The company reported a net loss of $85.7 million for Q4 2025, compared to a net loss of $78.2 million in Q4 2024. The increase in net loss was attributed to higher R&D expenses as the company advanced its pipeline programs.
Research and Development (R&D) Expenses R&D expenses were $72.5 million for Q4 2025, up 10% year-over-year. The increase was due to expanded clinical trial activities and preclinical development efforts.
General and Administrative (G&A) Expenses G&A expenses were $18.4 million for Q4 2025, reflecting a 5% increase year-over-year. This was mainly due to higher personnel-related costs and professional fees.
Cash and Cash Equivalents As of December 31, 2025, Intellia reported cash and cash equivalents of $450.2 million, down from $500.3 million as of December 31, 2024. The decrease was due to ongoing operational expenses and investments in pipeline development.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Potential risks associated with forward-looking statements as mentioned in the SEC filings. These risks could impact the company's operations, financials, or strategic plans.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Allen Baird
Batchelder Blair
Blair LLC
BofA Securities
Communications Leonard
Corporate Communications
Director Edward
Division Alec
Division Batchelder
Division EST
Division Hello
Division Jack
Division Jonathan
Division Lili
Division Shelby
Division Silvan
Division Terence
Division Thome
Division Yanan
EST Aleynick
Flynn Morgan
Full Conference
Hello Intellia
Hill RBC
Intellia minute
LLC Research
President Investor
Relations Corporate
Research Division
Securities LLC
Vice President
NTLA Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call revealed an increase in revenue but also a widening net loss due to higher R&D expenses. The cash reserves are decreasing, raising concerns about financial sustainability. The Q&A section did not provide clarity on management's responses, which may contribute to uncertainty. Despite a positive revenue growth, the financial health and lack of strategic updates suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8%.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
NTLA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
